Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Jan;65(1):227–230. doi: 10.1172/JCI109655

Elevated Thromboxane Levels in the Rat during Endotoxic Shock

PROTECTIVE EFFECTS OF IMIDAZOLE, 13-AZAPROSTANOIC ACID, OR ESSENTIAL FATTY ACID DEFICIENCY

J A Cook 1,2,3, W C Wise 1,2,3, P V Halushka 1,2,3
PMCID: PMC371359  PMID: 7350199

Abstract

The potential deleterious role of the proaggregatory vasoconstrictor, thromboxane A2, in endotoxic shock was investigated in rats. Plasma thromboxane A2 was determined by radioimmunoassay of its stable metabolite thromboxane B2. After intravenous administration of Salmonella enteritidis endotoxin (20 mg/kg), plasma thromboxane B2 levels increased from nondetectable levels (<375 pg/ml) in normal control rats to 2,054±524 pg/ml (n = 8), within 30 min to 2,071±429 at 60 min, and decreased to 1,119±319 pg/ml, at 120 min. Plasma levels of prostaglandin E also increased from 146±33 pg/ml in normal controls (n = 5) to 2,161±606 pg/ml 30 min after endotoxin (n = 5).

In contrast to shocked controls, rats pretreated with imidazole, a thromboxane synthetase inhibitor, or essential fatty acid-deficient rats, which are deficient in arachidonate and its metabolites, did not exhibit significant elevations in plasma levels of thromboxane B2. Imidazole did not however inhibit endotoxin-induced elevations in plasma prostaglandin E. Essential fatty acid deficiency significantly reduced mortality to lethal endotoxic shock. This refractoriness could be duplicated in normal rats pretreated with the fatty acid cyclo-oxygenase inhibitor, indomethacin (10 mg/kg), intravenously 30 min before endotoxin injection. Imidazole (30 mg/kg) administered intraperitoneally 1 h before or intravenously 30 min before endotoxin, also significantly (P < 0.01) reduced mortality from lethal endotoxin shock to 40% compared to a control mortality of 95% at 24 h. Likewise pretreatment with 13-azaprostanoic acid (30 mg/kg), a thromboxane antagonist, reduced mortality from endotoxic shock at 24 h from 100% in control rats to only 50% (P < 0.01). The results suggest that endotoxin induces increased synthesis of thromboxane A2 that may contribute to the pathogenesis of endotoxic shock.

Full text

PDF
228

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson F. L., Jubiz W., Tsagaris T. J., Kuida H. Endotoxin-induced prostaglandin E and F release in dogs. Am J Physiol. 1975 Feb;228(2):410–414. doi: 10.1152/ajplegacy.1975.228.2.410. [DOI] [PubMed] [Google Scholar]
  2. Brobmann G. F., Ulano H. B., Hinshaw L. B., Jacobson E. D. Mesenteric vascular responses to endotoxin in the monkey and dog. Am J Physiol. 1970 Nov;219(5):1464–1467. doi: 10.1152/ajplegacy.1970.219.5.1464. [DOI] [PubMed] [Google Scholar]
  3. Burch R. M., Knapp D. R., Halushka P. V. Vasopressin stimulates thromboxane synthesis in the toad urinary bladder: effects of imidazole. J Pharmacol Exp Ther. 1979 Sep;210(3):344–348. [PubMed] [Google Scholar]
  4. Cook J. A., Wise W. C., Callihan C. S. Resistance of essential fatty acid-deficient rats to endotoxic shock. Circ Shock. 1979;6(4):333–342. [PubMed] [Google Scholar]
  5. Fletcher J. R., Ramwell P. W. Lidocaine or indomethacin improves survival in baboon endotoxin shock. J Surg Res. 1978 Mar;24(3):154–160. doi: 10.1016/0022-4804(78)90168-3. [DOI] [PubMed] [Google Scholar]
  6. Kessler E., Hughes R. C., Bennett E. N., Nadela S. M. Evidence for the presence of prostaglandin-like material in the plasma of dogs with endotoxin shock. J Lab Clin Med. 1973 Jan;81(1):85–94. [PubMed] [Google Scholar]
  7. Le Breton G. C., Venton D. L., Enke S. E., Halushka P. V. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci U S A. 1979 Aug;76(8):4097–4101. doi: 10.1073/pnas.76.8.4097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Moncada S., Bunting S., Mullane K., Thorogood P., Vane J. R., Raz A., Needleman P. Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins. 1977 Apr;13(4):611–618. doi: 10.1016/0090-6980(77)90232-5. [DOI] [PubMed] [Google Scholar]
  9. Needleman P., Raz A., Ferrendelli J. A., Minkes M. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1716–1720. doi: 10.1073/pnas.74.4.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Needleman P., Wyche A., Raz A. Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest. 1979 Feb;63(2):345–349. doi: 10.1172/JCI109309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nijkamp F. P., Moncada S., White H. L., Vane J. R. Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets. Eur J Pharmacol. 1977 Jul 15;44(2):179–186. doi: 10.1016/0014-2999(77)90104-2. [DOI] [PubMed] [Google Scholar]
  12. Pennington D. G., Hyman A. L., Jaques W. E. Pulmonary vascular response to endotoxin in intact dogs. Surgery. 1973 Feb;73(2):246–255. [PubMed] [Google Scholar]
  13. Samuelsson B., Goldyne M., Granström E., Hamberg M., Hammarström S., Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem. 1978;47:997–1029. doi: 10.1146/annurev.bi.47.070178.005025. [DOI] [PubMed] [Google Scholar]
  14. Webb J. G., Saelens D. A., Halushka P. V. Biosynthesis of prostaglandin E by rat superior cervical ganglia. J Neurochem. 1978 Jul;31(1):13–19. doi: 10.1111/j.1471-4159.1978.tb12427.x. [DOI] [PubMed] [Google Scholar]
  15. Ziboh V. A., Vanderhoek J. Y., Lands W. E. Inhibition of sheep vesicular gland oxygenase by unsaturated fatty acids from skin of essential fatty acid deficient rats. Prostaglandins. 1974 Feb 10;5(3):233–240. doi: 10.1016/0090-6980(74)90050-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES